Format

Send to

Choose Destination
Am J Obstet Gynecol. 2016 Jan;214(1):15-21. doi: 10.1016/j.ajog.2015.06.067. Epub 2015 Jul 9.

Recurrent vulvovaginal candidiasis.

Author information

1
Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI. Electronic address: Jsobel@med.wayne.edu.

Abstract

Recurrent vulvovaginal candidiasis (RVVC) is a common cause of significant morbidity in women in all strata of society affecting millions of women worldwide. Previously, RVVC occurrence was limited by onset of menopause but the widespread use of hormone replacement therapy has extended the at-risk period. Candida albicans remains the dominant species responsible for RVVC, however optimal management of RVVC requires species determination and effective treatment measures are best if species-specific. Considerable progress has been made in understanding risk factors that determine susceptibility to RVVC, particularly genetic factors, as well as new insights into normal vaginal defense immune mechanisms and their aberrations in RVVC. While effective control of RVVC is achievable with the use of fluconazole maintenance suppressive therapy, cure of RVVC remains elusive especially in this era of fluconazole drug resistance. Vaccine development remains a critical challenge and need.

KEYWORDS:

Candida vaginitis; antifungals; antimycotics; vaginal candidosis; vulvovaginal candidiasis

Comment in

PMID:
26164695
DOI:
10.1016/j.ajog.2015.06.067
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center